2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 867

Termination of Tocilizumab-Treatment in Giant Cell Arteritis: Follow-up of Patients after the RCT (ClinicalTrials.gov registration number: NCT01450137)
Abstract Number: 868

Infections and the Risk of Incident Giant Cell Arteritis: A Population-Based, Case-Control Study
Abstract Number: 869

Low Numbers of CD16+ Monocytes Predict Shorter Time to Relapse in Polymyalgia Rheumatica
Abstract Number: 870

Contemporary Prevalence Estimates for Giant Cell Arteritis and Polymyalgia Rheumatica, 2015
Abstract Number: 871

Interleukin 33 Critically Regulates Angiogenesis and Inflammation in Large Vessels Vasculitis
Abstract Number: 872

New Insights into the Pathogenesis of Giant Cell Arteritis through a Genome-Wide Association Study
Abstract Number: 873

Interleukin-23 Stimulates Inflammatory and Proliferative Pathways in Giant Cell Arteritis
Abstract Number: 874

Expression and Function of IL-12/23 Related Cytokine Subunits (p35, p40 and p19) in Giant-Cell Arteritis Lesions. Potential Role of p40 in Promoting Th1 -Mediated Pathways
Abstract Number: 875

Pericardial Involvement in Biopsy-Proven Giant-Cell Arteritis (GCA) Patients Detected By CT Angiography (CTA): Prevalence at Diagnosis and Outcome with Glucocorticoid (GC) Treatment
Abstract Number: 876

Long Term Efficacy of Ustekinumab for the Treatment of Giant Cell Arteritis
Abstract Number: 877

Risk of Coronary Artery Disease in Patients with Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis
Abstract Number: 878

Giant-Cell Arteritis Related Stroke: A Retrospective Multicentre Case-Control Study
Abstract Number: 879

Associated Inflammatory Diseases in Takayasu’s Arteritis: The Many Faces of a Disease
Abstract Number: 880

Pilot Study of Microbubble Contrast-Enhanced Vascular Ultrasonography: A Novel Method of Detecting Large Vessel Vasculitis?
Abstract Number: 881

Cardiopulmonary Involvement in Takayasu Arteritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].